AnaptysBio, Inc. (ANABV)San Diego, United States |
USD
|
Hot Take ↕ | July 11, 2026, 6:53 a.m. UTC
The immediate catalyst here is the announced spin-off of First Tracks Biotherapeutics, which typically unlocks value for shareholders by separating distinct business lines. However, the underlying business remains a high-risk biotech venture with no dividend to provide a floor. Fundamentally, the company is generating significant revenue growth of over 150%, yet it is burning cash with negative profit margins and a negative return on equity, indicating that profitability is still far off. While the balance sheet shows a massive current ratio due to cash holdings, the debt-to-equity ratio is dangerously high at 781%, suggesting aggressive leverage relative to shareholder equity. The lack of any price history prevents a long-term trend assessment, leaving the investment thesis entirely dependent on the success of future drug candidates and the clean break from the spin-off. Without a payout and with volatile, unproven fundamentals, this remains a speculative hold rather than a conviction buy. |
| Attribute | Value |
|---|---|
| Debt to Equity Ratio | 781.08 |
| Revenue per Share | 8.158 |
| Beta | 0.41 |
| Profit Margins | -5.64% |
| Website | https://www.anaptysbio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.03778559 |
| Address1 | 10,770 Wateridge Circle |
| Address2 | Suite 210 |
| All Time High | 49.76 |
| All Time Low | 41.99 |
| Ask | 46.96 |
| Ask Size | 100 |
| Average Daily Volume10 Day | 2,110 |
| Average Volume | 2,110 |
| Average Volume10Days | 2,110 |
| Beta | 0.406 |
| Bid | 39.51 |
| Bid Size | 100 |
| Book Value | 1.328 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Currency | USD |
| Current Price | 43.8 |
| Current Ratio | 9.068 |
| Day High | 43.8 |
| Day Low | 42.0 |
| Debt To Equity | 781.08 |
| Ebitda | 48,455,000 |
| Ebitda Margins | 0.20653999 |
| Enterprise To Ebitda | 25.553 |
| Enterprise To Revenue | 5.278 |
| Enterprise Value | 1,238,175,616 |
| Exchange | NMS |
| Exchange Timezone Name | UTC |
| Fifty Day Average | 44.844 |
| Fifty Two Week High | 49.76 |
| Fifty Two Week Low | 41.99 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,775,482,200 |
| Float Shares | 17,263,040 |
| Free Cashflow | 19,342,876 |
| Full Time Employees | 104 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.42043 |
| Gross Profits | 98,633,000 |
| Industry | |
| Industry Key | |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. |
| Long Name | AnaptysBio, Inc. |
| Max Age | 86,400 |
| Message Board Id | finmb_28462113 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -13,232,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Open | 42.04 |
| Operating Cashflow | 19,697,000 |
| Operating Margins | 0.61803 |
| Phone | 858 362 6295 |
| Previous Close | 43.0 |
| Price Hint | 2 |
| Price To Book | 32.98193 |
| Profit Margins | -0.056399997 |
| Quick Ratio | 8.945 |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Regular Market Day High | 43.8 |
| Regular Market Day Low | 42.0 |
| Regular Market Open | 42.04 |
| Regular Market Previous Close | 43.0 |
| Regular Market Volume | 2,209 |
| Return On Assets | 0.07058 |
| Return On Equity | -0.24486 |
| Revenue Growth | 1.511 |
| Revenue Per Share | 8.158 |
| Sand P52 Week Change | 0.2568333 |
| Sector | |
| Sector Key | |
| Short Name | AnaptysBio, Inc. Common Stock When Issued |
| State | CA |
| Symbol | ANABV |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 311,638,016 |
| Total Cash Per Share | 10.84 |
| Total Debt | 290,640,000 |
| Total Revenue | 234,603,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 44.844 |
| Underlying Symbol | ANABV |
| Uuid | e220aee6-9eee-380a-94ad-ab2923270d92 |
| Volume | 2,209 |
| Website | https://www.anaptysbio.com |
| Zip | 92,121-5801 |